

ISPE Singapore affiliate conference – ICH Q12

ISPE Singapore affiliate's Conference 2021 was a platform for industry or regulatory agencies to understand each other regarding the new quality guidances, including ICH Q12. I enjoyed listening to **Dr. Subin** (**Sankarankutty,** Regulatory Consultant (Lead CMC Assessor), **Health Sciences Authority (HSA),** Singapore) and Xiaoping's (**Dr. Xiaoping Cao,** Senior Director, Head of GCMC China, **Pfizer**, Singapore) presentations. I understood the concerns coming from the agencies to implement ICH Q12 and also the eagerness of the industry to have ICH Q12 implemented.

Also from Q&A and a panel discussion that I moderated the day before, I learnt that there was a need to get the industries and agencies on the same page. The proper education and training for both industries and agencies should be in place to accelerate the implementation of ICH Q12.

On top of that, I also enjoyed the presentations by ex-GSK colleague, **David Loong** (Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy, **Merck Life Science,** Singapore). It gave me a different perspective on mRNA bioprocessing. David's presentation was followed by **Katarina Stenklo** (Enterprise Commercial Activation Leader**, Cytiva,** Sweden) who addressed vaccine demand with rapid capacity deployment of mRNA manufacturing. These two presentations provided a complete picture of mRNA manufacturing process and they were very educational.

I look forward to the next year ISPE Singapore affiliate conference in 2022 and hope we can have face-to-face meeting this time.

Alfonsus Karli
Conference Vice Chair & Chair, Regulatory Affairs, **ISPE** Singapore Affiliate